



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 14th November, 2016

**To,
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051**

Sub: - Outcome of Board Meeting held on 14th November, 2016

Dear Sir/Madam,

A meeting of the Board of Directors of the company was held on Monday, the 14th day of November, 2016 at 11:30 A.M. at the Corporate Office of the Company at Indore and concluded at 2.10 P.M. The Board *inter-alia* considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the quarter ended 30th September, 2016 for the financial year 2016-17.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith, Un-audited Financial Results (Standalone and Consolidated basis) of the Company along with Limited Review Report by the statutory auditors of the Company on the Un-audited financial results of the Company for the quarter ended 30th September, 2016.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

**Thanking You
For Parenteral Drugs (India) Limited**


Company Secretary





PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30th September 2016

PART -I							
(Rs in Lacs)							
Sr. No.	Particulars	Three months ended 30/09/2016 Unaudited	Preceding three months ended 30/06/2016 Unaudited	Corresponding three months ended 30/09/2015 Unaudited	Half Year ended 30/09/2016 Unaudited	Corresponding Half Year ended 30/09/2015 Unaudited	Previous year ended 31/03/2016 Audited
1	Income from Operation						
	(a) Net Sales/Income from Operations of Excise Duty) (Net	1769.61	1547.95	5869.48	3317.56	10964.24	14877.94
	(b) Other Operating Income	4.35	0.76	12.85	5.11	105.42	190.77
	Total Income From Operation (Net)	1773.96	1548.71	5882.33	3322.67	11,069.66	15068.71
2	Expenditure						
	a) Consumption of Material Consumed	408.83	525.49	973.49	934.32	4093.90	5566.98
	b) Purchase of Stock In Trade	276.16	238.62	3305.18	514.78	3305.18	4395.86
	c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade	87.79	124.02	179.00	211.81	74.73	2356.37
	d) Employee Benefit Expenses	356.68	348.42	209.98	705.10	635.12	1180.41
	e) Depreciation and Amortisation Expenses	451.60	451.60	525.88	903.20	1051.76	1706.41
	f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately	860.40	802.25	703.23	1662.65	1921.71	6118.24
	Total Expenses	2441.46	2490.40	5896.76	4931.86	11082.40	21324.27
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(667.50)	(941.69)	(14.43)	(1,609.19)	(12.74)	(6255.56)
4	Other Income		0.00				0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(667.50)	(941.69)	(14.43)	(1,609.19)	(12.74)	(6255.56)
6	Finance costs	1845.66	1767.97	1055.14	3613.63	2493.90	5800.55
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional items (5-6)	(2,513.16)	(2709.66)	(1,069.57)	(5,222.82)	(2,506.64)	(12056.11)
8	Exceptional items		0.00				(54.45)
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	(2,513.16)	(2709.66)	(1,069.57)	(5,222.82)	(2,506.64)	(12110.56)
10	Tax Expenses	(442.75)	(442.75)	0.00	(885.50)	6.01	(1261.27)
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(2,070.41)	(2266.91)	(1,069.57)	(4,337.32)	(2,512.65)	(10849.29)
12	Extraordinary items (net of tax expense)		0.00				0.00
13	Net Profit / (Loss) for the period (11 + 12)	(2,070.41)	(2266.91)	(1,069.57)	(4,337.32)	(2,512.65)	(10849.29)
14	Share of profit / (loss) of associates*						
15	Minority interest *						
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,070.41)	(2266.91)	(1,069.57)	(4,337.32)	(2,512.65)	(10849.29)
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						(1680.34)
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(6.94)	(7.60)	(3.59)	(14.55)	(8.43)	(36.39)
	(b) Diluted	(6.94)	(7.60)	(3.59)	(14.55)	(8.43)	(36.39)
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised):						
	(a) Basic	(6.94)	(7.60)	(3.59)	(14.55)	(8.43)	(36.39)
	(b) Diluted	(6.94)	(7.60)	(3.59)	(14.55)	(8.43)	(36.39)

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013.
Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2016	31.03.2016
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4285.42	4285.42
	(b) Reserves and Surplus	20319.39	24656.71
	Sub-total - Shareholders' funds	24604.81	28942.13
2	Call money against Preference Shares	0.00	0.00
3	Minority interest *	0.00	0.00
4	Non-current liabilities		
	(a) Long-term borrowings	43476.29	37760.24
	(b) Deferred tax liabilities (net)	0.00	0.00
	Sub-total - Non-current liabilities	43476.29	37760.24
5	Current liabilities		
	(a) Short-term borrowings	12793.54	12787.36
	(b) Trade payables	1632.38	1728.27
	(c) Other current liabilities	6996.63	9212.77
	(d) Short-term provisions	695.87	585.05
	Sub-total - Current liabilities	22118.42	24313.45
	TOTAL - EQUITY AND LIABILITIES	90199.52	91015.82
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	64419.99	65323.19
	(b) Non-current investments	13868.85	13868.85
	(c) Long-term loans and advances	740.85	762.44
	(d) Other non-current assets	0.63	0.63
	(e) Deferred tax assets (net)	995.81	110.31
	Sub-total - Non-current assets	80026.13	80065.42
2	Current assets		
	(a) Inventories	823.21	1509.91
	(b) Trade receivables	8345.27	8515.74
	(c) Cash and cash equivalents	226.64	229.42
	(d) Short-term loans and advances	211.93	138.66
	(e) Other current assets	566.34	556.66
	Sub-total - Current assets	10173.39	10950.39
	TOTAL - ASSETS	90199.52	91015.82

NOTES :

- The above results were reviewed by the audit committee and thereafter approved by Board of Directors in their meeting held on 14th November 2016 respectively.
- The statutory auditors of the company have carried out limited review of the aforesaid results.
- At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
- The figures for previous year/period have been regrouped/rearranged wherever found necessary.
- The standalone financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

Place: Indore
Date: 14th November 2016

For and on behalf of Board of Directors



Vinod Kumar Gupta
Managing Director
DIN: 00039145

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com


Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2016

PART - I								(Rs in Lacs)
Sr. No.	Particulars	Three months ended 30/09/2016 Unaudited	Preceding Three months ended 30/06/2016 Unaudited	Corresponding three months ended 30/09/2015 Unaudited	Half Year ended 30/09/2016 Unaudited	Corresponding Half Year ended 30/09/2015 Unaudited	Previous year ended 31/03/2016 Audited	
1	Income from Operation (a) Net Sales/Income from Operations of Excise Duty) (Net (b) Other Operating Income Total Income From Operation (Net)	6262.60 5.25 6267.85	7334.95 4.09 7339.04	7998.16 29.53 8027.69	13597.55 9.34 13606.89	16802.97 124.18 16927.15	26027.30 205.27 26232.57	
2	Expenditure a) Cost of Material Consumed b) Purchase of Stock In Trade c) Change in Inventories of Finished Goods, Work in Progress and Stock In trade d) Employee Benefit Expenses e) Depreciation and Amortisation Expenses f) Other Expenditure (Any Item Exceeding 10% of the Total expenses relating to continuing operations to be shown separately Total Expenses	2988.07 1449.74 -340.80 492.42 606.40 1548.09 6743.92	2719.87 2123.41 534.08 482.41 594.75 1646.47 8100.99	1914.98 3739.94 270.78 324.58 676.14 1161.79 8088.21	5707.94 3573.15 193.28 974.83 1201.15 3194.56 14844.91	6251.07 4599.34 567.90 882.25 1352.28 3221.74 16874.58	11071.63 5088.67 2209.76 1687.06 2279.00 9545.13 31881.25	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(476.07)	(761.95)	(60.52)	(1,238.02)	52.57	(5648.68)	
4	Other Income		0.00					
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(476.07)	(761.95)	(60.52)	(1,238.02)	52.57	(5648.68)	
6	Finance costs	2139.91	2071.14	1341.40	4211.05	3119.24	6987.62	
7	Profit/(Loss) from ordinary activities after finance costs but before Exceptional items (5-6)	(2,615.98)	(2,833.09)	(1,401.92)	(5,449.07)	(3,066.67)	(12636.30)	
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	54.44	
9	Profit / (Loss) from ordinary activities before tax(7 + 8)	(2,615.98)	(2,833.09)	(1,401.92)	(5,449.07)	(3,066.67)	(12690.74)	
10	Tax Expenses	-401.68	-401.68	52.08	-803.36	110.17	(1035.82)	
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(2,214.30)	(2,431.41)	(1,454.00)	(4,645.71)	(3,176.84)	(11654.92)	
12	Extraordinary items (net of tax expense Lakhs)							
13	Net Profit / (Loss) for the period (11 + 12)	(2,214.30)	(2,431.41)	(1,454.00)	(4,645.71)	(3,176.84)	(11654.92)	
14	Share of profit / (loss) of associates *							
15	Minority interest *							
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(2,214.30)	(2,431.41)	(1,454.00)	(4,645.71)	(3,176.84)	(11654.92)	
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	2981.63	2981.63	2981.63	2981.63	2981.63	2981.63	
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						1430.58	
19 i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic (b) Diluted	(7.43) (7.43)	(8.15) (8.15)	(4.88) (4.88)	(15.58) (15.58)	(10.65) (10.65)	(39.09) (39.09)	
19 ii	Earnings per share (After extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic (b) Diluted	(7.43) (7.43)	(8.15) (8.15)	(4.88) (4.88)	(15.58) (15.58)	(10.65) (10.65)	(39.09) (39.09)	

* Applicable in the case of consolidated results.

Note: The classification / disclosure of items in the financial results shall be in accordance with the Schedule III of the Companies Act, 2013.

Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Statement of Assets and Liabilities

Sr. No.	Particulars	30.09.2016	31.03.2016
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	4770.42	4770.42
	(b) Reserves and Surplus	23122.10	27767.64
	Sub-total - Shareholders' funds	27892.52	32538.06
	Share application money pending allotment	0.00	0.00
3	Minority interest *	65.04	65.04
4	Non-current liabilities		
	(a) Long-term borrowings	48974.01	43579.78
	(b) Deferred tax liabilities (net)	0.00	437.92
	Sub-total - Non-current liabilities	48974.01	44017.70
5	Current liabilities		
	(a) Short-term borrowings	15224.91	15221.17
	(b) Trade payables	6560.12	3891.44
	(c) Other current liabilities	7573.75	10028.01
	(d) Short-term provisions	783.06	837.30
	Sub-total - Current liabilities	30141.84	29977.92
	TOTAL - EQUITY AND LIABILITIES	107073.41	106598.72
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	75110.24	76311.38
	(b) Goodwill on consolidation *	12870.65	12870.65
	(c) Non-current investments	1.10	1.10
	(d) Long-term loans and advances	988.98	1014.72
	(e) Other non-current assets	85.50	85.41
	(f) Deferred tax assets(net)	365.44	
	Sub-total - Non-current assets	89421.91	90283.26
2	Current assets		
	(a) Inventories	5371.87	5627.36
	(b) Trade receivables	10737.30	9241.72
	(c) Cash and cash equivalents	446.32	456.86
	(d) Short-term loans and advances	365.40	215.80
	(e) Other current assets	730.61	773.71
	Sub-total - Current assets	17651.50	16315.45
	TOTAL - ASSETS	107073.41	106598.72

NOTES :

- The above results were reviewed by the audit committee and thereafter approved by Board of Directors in their meeting held on 14th November 2016
 - The statutory auditors of the company have carried out limited review of the aforesaid results.
 - At the moment the company is having only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS-17) as the business under proposed real estate segment is yet to commence.
 - The figures for previous year/period have been regrouped/rearranged wherever found necessary.
 - The consolidated financial results of the company are available on the website of the company i.e. www.pdindia.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- The key standalone financial results are given below:

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Prev. Yr. Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
1	Income from operations & other income	1,773.96	1,548.71	5,882.33	3,322.67	11,069.66	15,068.71
2	Profit/Loss before tax	(2,513.16)	(2,709.66)	(1,069.57)	(5,222.82)	(2,506.64)	(12,110.56)
3	Profit/Loss after tax	(2,070.41)	(2,266.91)	(1,069.57)	(4,337.32)	(2,512.65)	(10,849.29)

Place: Indore
Date: 14th November 2016

For and on behalf of Board of Directors



Vinod Kumar Gupta
Managing Director
DIN: 00039145

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

T.N. UNNI & Co.
Chartered Accountants

402, Alankar Point,
4-A, Rajgarh Kothi,
Geeta Bhawan Square,
A.B.Road,
Indore- 452001

Limited Review Report

Review Report to
**National Stock Exchange of India Limited/
Bombay Stock Exchange Limited**

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the period ended **30th September, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.


A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: **INDORE**
Date: **14/11/2016**

For T.N. UNNI & Co.
Chartered Accountants




T.N. Unni
(Partner)
M. No. 14520
F.R.N. 004890C